RE:Financial ResultsThe next 1 1/2 months is tax loss selling and this stock is down 53% this year.
It will be interesting to see how much cash is left.
The new Director suggests there could be a strong new President and CEO appointed soon which could be important for the story and a key catalyst.
With the avenanthramide clinical trial expected to complete the 2 dose portion of the Phase I portion of the clinical trial by the end of the year the preliminary efficacy portion of the trial can be completed next year. Having safety/tolerability and preliminary efficacy data in humans with mild inflation is a defining moment fot the asset. We currently have no preclinical or clinical data for the pill other than there have been no serious adverse events.
PGX is expected to reach the decision point for mass industrialization in the next 1 1/2 months. This is a defining moment for PGX and a potential transformative catalyst.
The diagnostic is a wild card; particularily at this stock price.We need to find out the forward path.
As for AEZS's pipeline assets the S&P Biotech ETF is at 52-week highs. We await the forward path.